N/A N=21 ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
Aortic Dissection
Primary: All Cause Mortality at 30 Days Post-procedure — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
Aortic Dissection
Primary: All Cause Mortality. — 4 participants
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
N/A N=50 Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection
Type B Aortic Dissection
Primary: All-cause Mortality Incidence Through 30 Days Post-treatment — 5 participants — p=.006
N/A N=61 A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection
Aortic Diseases
Primary: Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation — 15; 31 participants — p=<0.001
N/A N=88 Angiotensin II Pathway and Postoperative Hypoxemia
Aortic Dissection
Primary: The Difference Concentrations of ANG II in Serum Between Patients With and Without Postoperative Hypoxemia. — 100; 78.5 pg / mL
N/A N=73 Zenith® Dissection Clinical Trial
Aortic Dissection
Primary: Number of Participants With Freedom From Major Adverse Events — 48 participants
N/A N=26 Zenith® Dissection Endovascular System
Aortic Dissection
Primary: Number of Patients With Major Complications — 2; 4; 2; 3 participants
N/A N=100 ADVANCE Direct Aortic Study
Aortic Stenosis · Valvular Heart Disease
Primary: All-cause Mortality — 4.4 Percentage of subjects
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=613 Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
Abdominal Aortic Aneurysm
Primary: Mortality — 111; 112; 133; 130 Participants
N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
N/A N=32 Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending TAA and Chronic Dissections
Aortic Aneurysm, Thoracic, Chronic Type B Dissection
Primary: 30 Day Composite Safety Endpoint — 10.0 percentage of participants
N/A N=31 Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms
Aortic Aneurysm, Thoracic
Primary: Number of Participants With Successful Study Device Access — 31 Participants
Phase 4 N=59 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain
Chest Pain Syndrome
Primary: Length of Hospital Stay — 7.63; 8.20 Hours — p=0.79
N/A N=30 Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation
Native and Valve in Valve Aortic Valve Failure
Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants
Phase 2 N=66 Evaluation of Predictors of Aortic Aneurysm Growth and Rupture
Abdominal Aortic Aneurysm
Primary: Annual Aneurysm Growth Rate Between Patients With and Without Micro Bubble Uptake — 3.0; 3.2 mm/year
Phase 2 N=55 Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Surgical Procedures
Primary: Change From Baseline to Peak in Cerebrospinal Fluid (CSF) S100 Beta Within 48 Hours Following Descending Thoracic Aorta/Thoracoabdominal Aortic Aneurysm (DTA/TAAA)…
N/A N=20 Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis
Aortic Valve Stenosis
Primary: Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA). — 75.0; 87.5 percentage of participants analyzed — p=0.002
N/A N=50 Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury
Blunt Thoracic Aortic Injury
Primary: All-cause Mortality Within 30-days of the Index Procedure — 4 participants
Phase 2 N=261 Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
Aneurysm
Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…
N/A N=19 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
N/A N=160 Valor II: The Valiant Thoracic Stent Graft System Clinical Study
Thoracic Aortic Aneurysm
Primary: Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint) — 94.8 Percentage of participants
N/A N=51 Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
Aneurysm
Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024
N/A N=20 Engager Direct Aortic Clinical Study
Aortic Valve Stenosis
Primary: Acute Delivery System Success — 95.0 percentage of participants
N/A N=51 Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection
Thoracic Injuries
Primary: All Cause Mortality — 4 participants
Phase 2 N=224 AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
N/A N=55 Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis
Aortic Valve Stenosis
Primary: Composite Success of Improvement in New York Heart Association (NYHA) Class and a Performance Goal for Effective Orifice Area (EOA). — 93.6; 91.7 percentage of…
N/A N=132 Biomarkers in Thoracic Aorta Surgery
Aortic Aneurysm · Thoracoabdominal Aneurysm · Aortic Dissection
Primary: Number of Total Postoperative Complications — 69 post-operative complications
N/A N=235 Preferences for Open Vs. Endovascular Repair for Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Veteran Preference for Repair Type — 25; 25; 95; 80 Participants